Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products - PubMed (original) (raw)
Review
Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products
Maaike E Ressing et al. Semin Cancer Biol. 2008 Dec.
Abstract
Upon primary infection, EBV establishes a latent infection in B cells, characterized by maintenance of the viral genome in the absence of viral replication. The Epstein-Barr Nuclear Antigen 1 (EBNA1) plays a crucial role in maintenance of the viral DNA episome and is consistently expressed in all EBV-associated malignancies. Compared to other EBV latent gene products, EBNA1 is poorly recognized by CD8(+) T lymphocytes. Recent studies are discussed that shed new light on the mechanisms that underlie this unusual lack of CD8(+) T cell activation. Whereas the latent phase is characterized by the expression of a limited subset of viral gene products, the full repertoire of over 80 EBV lytic gene products is expressed during the replicative phase. Despite this abundance of potential T cell antigens, which indeed give rise to a strong response of CD4(+) and CD8(+) T lymphocytes, the virus can replicate successfully. Evidence is accumulating that this paradoxical situation is the result of actions of multiple viral gene products, inhibiting discrete stages of the MHC class I and class II antigen presentation pathways. Immediately after initiation of the lytic cycle, BNLF2a prevents peptide-loading of MHC class I molecules through inhibition of the Transporter associated with Antigen Processing, TAP. This will reduce presentation of viral antigens by the large ER-resident pool of MHC class I molecules. Synthesis of new MHC class I molecules is blocked by BGLF5. Viral-IL10 causes a reduction in mRNA levels of TAP1 and bli/LMP2, a subunit of the immunoproteasome. MHC class I molecules present at the cell surface are downregulated by BILF1. Also the antigen presenting capacity of MHC class II molecules is severely compromised by multiple EBV lytic gene products, including gp42/gH/gL, BGLF5, and vIL-10. In this review, we discuss how concerted actions of these EBV lytic proteins result in highly effective interference with CD8(+) and CD4(+) T cell surveillance, thereby providing the virus with a window for undisturbed generation of viral progeny.
Similar articles
- Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, Hislop AD, Rowe M. Quinn LL, et al. PLoS Pathog. 2014 Aug 21;10(8):e1004322. doi: 10.1371/journal.ppat.1004322. eCollection 2014 Aug. PLoS Pathog. 2014. PMID: 25144360 Free PMC article. - Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, Moosmann A, Hammerschmidt W. Albanese M, et al. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6467-E6475. doi: 10.1073/pnas.1605884113. Epub 2016 Oct 3. Proc Natl Acad Sci U S A. 2016. PMID: 27698133 Free PMC article. - Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD. Croft NP, et al. PLoS Pathog. 2009 Jun;5(6):e1000490. doi: 10.1371/journal.ppat.1000490. Epub 2009 Jun 26. PLoS Pathog. 2009. PMID: 19557156 Free PMC article. - Immune Evasion by Epstein-Barr Virus.
Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ. Ressing ME, et al. Curr Top Microbiol Immunol. 2015;391:355-81. doi: 10.1007/978-3-319-22834-1_12. Curr Top Microbiol Immunol. 2015. PMID: 26428381 Review. - Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C, Pyndiah S, Apcher S, Mazars A, Manoury B, Ammari N, Nylander K, Voisset C, Blondel M, Fåhraeus R. Daskalogianni C, et al. J Pathol. 2015 Jan;235(2):334-41. doi: 10.1002/path.4431. J Pathol. 2015. PMID: 25186125 Review.
Cited by
- DRB1 locus alleles of HLA class II are associated with modulation of the immune response in different serological profiles of HIV-1/Epstein-Barr virus coinfection in the Brazilian Amazon region.
Pereira LMS, Dos Santos França E, Costa IB, Lima IT, Jorge EVO, de Souza Mendonça Mattos PJ, Freire ABC, de Paula Ramos FL, Monteiro TAF, Macedo O, Sousa RCM, Freitas FB, Costa IB, Vallinoto ACR. Pereira LMS, et al. Front Med (Lausanne). 2024 Jun 12;11:1408290. doi: 10.3389/fmed.2024.1408290. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38933108 Free PMC article. - Epstein-Barr Viruses: Their Immune Evasion Strategies and Implications for Autoimmune Diseases.
Zhao Y, Zhang Q, Zhang B, Dai Y, Gao Y, Li C, Yu Y, Li C. Zhao Y, et al. Int J Mol Sci. 2024 Jul 26;25(15):8160. doi: 10.3390/ijms25158160. Int J Mol Sci. 2024. PMID: 39125729 Free PMC article. Review. - Comparative Immunoreactivity Analyses of Hantaan Virus Glycoprotein-Derived MHC-I Epitopes in Vaccination.
Sun B, Zhang J, Wang J, Liu Y, Sun H, Lu Z, Chen L, Ding X, Pan J, Hu C, Yang S, Jiang D, Yang K. Sun B, et al. Vaccines (Basel). 2022 Apr 6;10(4):564. doi: 10.3390/vaccines10040564. Vaccines (Basel). 2022. PMID: 35455313 Free PMC article. - Concept and application of a computational vaccinology workflow.
Söllner J, Heinzel A, Summer G, Fechete R, Stipkovits L, Szathmary S, Mayer B. Söllner J, et al. Immunome Res. 2010 Nov 3;6 Suppl 2(Suppl 2):S7. doi: 10.1186/1745-7580-6-S2-S7. Immunome Res. 2010. PMID: 21067549 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous